+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis



Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis



Laboratory Investigation; a Journal of Technical Methods and Pathology 80(8): 1195-1205



Maintenance of the invasive pannus in rheumatoid arthritis is an integral part of disease progression. The synovial vasculature plays an important role in the delivery of nutrients, oxygen, and inflammatory cells to the synovium. Vascular endothelial growth factor (VEGF), an endothelial mitogen expressed by cells within the synovial membrane, is thought to contribute to the formation of synovial blood vessels. Our objective in this study was to measure the kinetics of VEGF production in a murine model of collagen-induced arthritis and to determine whether VEGF blockade reduces disease progression. Synovial cells isolated from the knee joints of naive or sham-immunized mice, or from mice immunized with collagen but without arthritis, released little or no detectable VEGF. Onset of arthritis was associated with expression of VEGF mRNA and protein. The levels of VEGF secreted by synovial cells isolated from the joints of mice with severe arthritis were significantly higher than from mice with mild disease. To block VEGF activity, animals were treated after arthritis onset with a soluble form of the Flt-1 VEGF receptor (sFlt), which was polyethylene glycol (PEG)-linked to increase its in vivo half-life. Treatment of arthritic mice with sFlt-PEG significantly reduced both clinical score and paw swelling, compared with untreated or control-treated (heat-denatured sFlt-PEG) animals. There was also significantly less joint inflammation and reduced bone and cartilage destruction in sFlt-PEG-treated animals, as assessed by histology. Our data demonstrate that, in collagen-induced arthritis, expression of the potent angiogenic cytokine VEGF correlates with disease severity. Furthermore, specific blockade of VEGF activity results in attenuation of arthritis in both macroscopic and microscopic parameters. These observations indicate that blood vessel formation is integral to the development of arthritis and that blockade of VEGF activity might be of therapeutic benefit in rheumatoid arthritis.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 047839472

Download citation: RISBibTeXText

PMID: 10950110

DOI: 10.1038/labinvest.3780127


Related references

Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Laboratory Investigation 80(8): 1195-1205, 2000

Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis. Gene Therapy 10(23): 1950-1960, 2003

Local gene transfer of a TNF-alpha soluble receptor by an adenoviral vector delays the onset and reduces the severity of collagen induced arthritis in mice. Arthritis & Rheumatism 41(9 Suppl. ): S96, 1998

Treatment with anti-NAP-mAb reduces disease severity in murine model of novel angiogenic protein-induced or ovalbumin-induced arthritis. 2012

Treatment with anti-NAP monoclonal antibody reduces disease severity in murine model of novel angiogenic protein-induced or ovalbumin-induced arthritis. Clinical and Experimental Immunology 171(2): 155-163, 2013

Antagonism of the human epidermal growth factor receptor family controls disease severity in murine collagen-induced arthritis. Arthritis and Rheumatism 58(10): 3071-3080, 2008

Oestrogen induced suppression of collagen arthritis: I. Long term oestradiol treatment of DBA/1 mice reduces severity and incidence of arthritis and decreases the anti type II collagen immune response. Clinical and Experimental Immunology 70(2): 372-378, 1987

The angiogenesis inhibitor protease-activated kringles 1-5 reduces the severity of murine collagen-induced arthritis. Arthritis Research and Therapy 5(1): R32-R39, 2003

Recombinant soluble human FcgammaR1A (CD64A) reduces inflammation in murine collagen-induced arthritis. Journal of Immunology 182(11): 7272-7279, 2009

An anti-murine IL-22 monoclonal antibody decreases disease severity in a murine model of collagen induced arthritis. European Cytokine Network 14(Suppl. 3): 129, 2003

A chemokine receptor antagonist reduces the incidence and severity of collagen induced arthritis in DBA/1 mice. Immunology Letters 56(Part-P1): 42-43, 1997

N-α-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis. Journal of Immunology 186(7): 4396-4404, 2011

BML-111, a lipoxin receptor agonist, modulates the immune response and reduces the severity of collagen-induced arthritis. Inflammation Research 57(4): 157-162, 2008

Polydeoxyribonucleotide reduces cytokine production and the severity of collagen-induced arthritis by stimulation of adenosine A(₂A) receptor. Arthritis and Rheumatism 63(11): 3364-3371, 2011

A fish oil diet reduces the severity of collagen induced arthritis after onset of the disease. Clinical and Experimental Immunology 73(2): 328-332, 1988